“Smoldering multiple myeloma” (SMM) is a blood and bone marrow disorder which can lead to multiple myeloma, a deadly cancer.

1 At present, FDA has approved elranatamab for patients with multiple myeloma who are relapsed/refractory after at least 4 ...

Tony Newberne is a high-risk myeloma survivor. He is also a CPT, dietary manager, and patient advocate for several nonprofits ...

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Anita D'Souza, MD, discusses an abstract looking at the combination of teclistamab-cqyv, daratumumab, and pomalidomide in 2 ...

Study of frail older adult patients with myeloma showed reduced disease progression and death with a regimen reducing dexamethasone exposure.

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

Including 24-hour urine testing in multiple myeloma response assessments is largely unnecessary, a new phase 3 trial suggests ...